IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v14y2023i1d10.1038_s41467-023-37184-7.html
   My bibliography  Save this article

The evolution of antibiotic resistance is associated with collateral drug phenotypes in Mycobacterium tuberculosis

Author

Listed:
  • Natalie J. E. Waller

    (University of Otago
    University of Auckland)

  • Chen-Yi Cheung

    (University of Otago)

  • Gregory M. Cook

    (University of Otago
    University of Auckland)

  • Matthew B. McNeil

    (University of Otago
    University of Auckland)

Abstract

The increasing incidence of drug resistance in Mycobacterium tuberculosis has diminished the efficacy of almost all available antibiotics, complicating efforts to combat the spread of this global health burden. Alongside the development of new drugs, optimised drug combinations are needed to improve treatment success and prevent the further spread of antibiotic resistance. Typically, antibiotic resistance leads to reduced sensitivity, yet in some cases the evolution of drug resistance can lead to enhanced sensitivity to unrelated drugs. This phenomenon of collateral sensitivity is largely unexplored in M. tuberculosis but has the potential to identify alternative therapeutic strategies to combat drug-resistant strains that are unresponsive to current treatments. Here, by using drug susceptibility profiling, genomics and evolutionary studies we provide evidence for the existence of collateral drug sensitivities in an isogenic collection M. tuberculosis drug-resistant strains. Furthermore, in proof-of-concept studies, we demonstrate how collateral drug phenotypes can be exploited to select against and prevent the emergence of drug-resistant strains. This study highlights that the evolution of drug resistance in M. tuberculosis leads to collateral drug responses that can be exploited to design improved drug regimens.

Suggested Citation

  • Natalie J. E. Waller & Chen-Yi Cheung & Gregory M. Cook & Matthew B. McNeil, 2023. "The evolution of antibiotic resistance is associated with collateral drug phenotypes in Mycobacterium tuberculosis," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    • Handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-37184-7
    DOI: 10.1038/s41467-023-37184-7
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-023-37184-7
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-023-37184-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Linda B. S. Aulin & Apostolos Liakopoulos & Piet H. Graaf & Daniel E. Rozen & J. G. Coen van Hasselt, 2021. "Design principles of collateral sensitivity-based dosing strategies," Nature Communications, Nature, vol. 12(1), pages 1-14, December.
    2. Daniel Nichol & Joseph Rutter & Christopher Bryant & Andrea M. Hujer & Sai Lek & Mark D. Adams & Peter Jeavons & Alexander R. A. Anderson & Robert A. Bonomo & Jacob G. Scott, 2019. "Antibiotic collateral sensitivity is contingent on the repeatability of evolution," Nature Communications, Nature, vol. 10(1), pages 1-10, December.
    3. Nicole L. Podnecky & Elizabeth G. A. Fredheim & Julia Kloos & Vidar Sørum & Raul Primicerio & Adam P. Roberts & Daniel E. Rozen & Ørjan Samuelsen & Pål J. Johnsen, 2018. "Conserved collateral antibiotic susceptibility networks in diverse clinical strains of Escherichia coli," Nature Communications, Nature, vol. 9(1), pages 1-11, December.
    4. Tiago Beites & Kathryn O’Brien & Divya Tiwari & Curtis A. Engelhart & Shaun Walters & Jenna Andrews & Hee-Jeong Yang & Michelle L. Sutphen & Danielle M. Weiner & Emmanuel K. Dayao & Matthew Zimmerman , 2019. "Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development," Nature Communications, Nature, vol. 10(1), pages 1-12, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Jeff Maltas & Kevin B Wood, 2019. "Pervasive and diverse collateral sensitivity profiles inform optimal strategies to limit antibiotic resistance," PLOS Biology, Public Library of Science, vol. 17(10), pages 1-34, October.
    2. Sara Hernando-Amado & Pablo Laborda & José Luis Martínez, 2023. "Tackling antibiotic resistance by inducing transient and robust collateral sensitivity," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    3. Shraddha Karve & Andreas Wagner, 2022. "Environmental complexity is more important than mutation in driving the evolution of latent novel traits in E. coli," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    4. Qian Li & Shang Chen & Kui Zhu & Xiaoluo Huang & Yucheng Huang & Zhangqi Shen & Shuangyang Ding & Danxia Gu & Qiwen Yang & Hongli Sun & Fupin Hu & Hui Wang & Jiachang Cai & Bing Ma & Rong Zhang & Jian, 2022. "Collateral sensitivity to pleuromutilins in vancomycin-resistant Enterococcus faecium," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    5. Tiago Beites & Robert S. Jansen & Ruojun Wang & Adrian Jinich & Kyu Y. Rhee & Dirk Schnappinger & Sabine Ehrt, 2021. "Multiple acyl-CoA dehydrogenase deficiency kills Mycobacterium tuberculosis in vitro and during infection," Nature Communications, Nature, vol. 12(1), pages 1-10, December.
    6. Cheng Zhao & Yu Wang & Ranya Mulchandani & Thomas P. Van Boeckel, 2024. "Global surveillance of antimicrobial resistance in food animals using priority drugs maps," Nature Communications, Nature, vol. 15(1), pages 1-10, December.
    7. Dennis Y. Liu & Laura Phillips & Darryl M. Wilson & Kelly M. Fulton & Susan M. Twine & Alex Wong & Roger G. Linington, 2023. "Collateral sensitivity profiling in drug-resistant Escherichia coli identifies natural products suppressing cephalosporin resistance," Nature Communications, Nature, vol. 14(1), pages 1-14, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-37184-7. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.